56 completed, 15 recruiting, 13 unknown, 12 terminated. 109 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 109 | Completed 56, Recruiting 15, Unknown 13, Terminated 12, Not yet recruiting 5, Withdrawn 5, Enrolling by invitation 2, Active not recruiting 1 |
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety And Field Evaluation of Plasma Lyophilized for Acute and Surgical Management Applications Freeze-Dried Plasma, Conventional Plasma - Thromboembolic Event, FDP | Phase 4 | Not yet recruiting | Teleflex | 867 | 2027-10-01 | 2026-09-30 |
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease Apixaban - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 4 | Not yet recruiting | James Bayley | 50 | 2026-08-01 | 2026-07-20 |
| Statins to Prevent Cancer Associated Blood Clots Rosuvastatin, Placebo Drug - Venous Thromboembolism, Cancer | Phase 4 | Recruiting | Brigham and Women's Hospital | 4000 | 2026-06-11 | 2026-09-16 |
| A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens Enhanced dermatologic management, Enhanced IRR Prophylaxis, Enhanced VTE Prophylaxis (Cohort 1 only) - NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism) | Phase 4 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 122 | 2026-04-30 | 2026-03-13 |
| Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis batroxobin, Anticoagulation Agents - Cerebral Venous Thrombosis | Phase 4 | Recruiting | Xuanwu Hospital, Beijing | 72 | 2026-01-30 | 2026-01-20 |
| Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention rivaroxaban (10mg), Enoxaparin 40 mg SC - Deep Venous Thromboses, Laparotomy Patients | Phase 4 | Recruiting | Mayo Hospital Lahore | 212 | 2025-10-10 | 2025-11-21 |
| Apixaban or Enoxaparin After Head and Neck Cancer Surgery Enoxaparin, Apixaban - Venous Thromboembolism, Head and Neck Cancer | Phase 4 | Recruiting | Kiranya Arnold | 76 | 2025-10-01 | 2025-10-08 |
| Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients Warfarin (low-intensity anticoagulation), Warfarin (standard anticoagulation) - Advanced Heart Failure, Left Ventricular Assist Devices | Phase 4 | Not yet recruiting | Asan Medical Center | 94 | 2025-10-01 | 2025-07-23 |
| Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis Experimental: Hyperslim, Active Comparator #1 - Venous Thromboembolism (VTE), Intensive Care Medicine | Phase 4 | Recruiting | Science Valley Research Institute | 50 | 2025-05-25 | 2025-05-06 |
| Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk Low molecular weight heparin - Venous Thromboembolism (VTE), Post Partum Women | Phase 4 | Recruiting | University Hospital, Brest | 2400 | 2025-05-16 | 2026-06-10 |
| Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage tranexamic acid, normal saline - Postpartum Hemorrhage, Systemic Autoimmune Diseases | Phase 4 | Recruiting | RenJi Hospital | 276 | 2025-01-06 | 2025-03-17 |
| Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis Anticoagulation Therapy - Venous Thromboembolism, Cancer | Phase 4 | Recruiting | Ottawa Hospital Research Institute | 330 | 2024-12-19 | 2026-09-21 |
| Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation Anti Xa dosage, Dosage of PT-INR - Non Valvular Atrial Fibrillation | Phase 4 | Enrolling by invitation | Les Laboratoires des Médicaments Stériles | 120 | 2024-12-01 | 2025-03-06 |
| inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT Short duration prophylaxis, Higher intensity and longer duration prophylaxis, Control - Venous Thromboembolism, Venous Thromboses | Phase 4 | Recruiting | Leiden University Medical Center | 10078 | 2024-11-11 | 2026-09-08 |
| Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support Enoxaparin Injectable Solution, Argatroban, 1 Mg/mL Intravenous Solution, Unfractionated heparin - Respiratory Insufficiency, Circulatory Failure | Phase 4 | Recruiting | Medical University of Vienna | 90 | 2024-07-30 | 2024-10-29 |
| Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial Apixaban 2.5 MG - Venous Thromboembolism, Bleeding | Phase 4 | Recruiting | Clinical Urology and Epidemiology Working Group | 5436 | 2024-06-06 | 2025-05-28 |
| TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study Tranexamic acid, No Tranexamic acid - Venous Thromboembolism, Venous Thromboses | Phase 4 | Unknown | University Health Network, Toronto | 20 | 2024-06-01 | 2024-06-12 |
| VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization rivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures - Peripheral Arterial Disease, Venous Thormboembolism | Phase 4 | Recruiting | Science Valley Research Institute | 100 | 2024-02-24 | 2025-03-12 |
| Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery TXA, TEG6 - Arthritis Knee, Spine Fusion | Phase 4 | Unknown | Konkuk University Medical Center | 148 | 2024-02-10 | 2024-05-14 |
Showing 20 of 109. Sign in to see all of them.
Venous Thromboembolism (68) · Venous Thrombosis (24) · Pulmonary Embolism (21) · Thrombosis (17) · Hemorrhage (13) · Atrial Fibrillation (5) · Neoplasms (4) · Wounds and Injuries (4) · Hemostatic Disorders (3) · Renal Insufficiency (3) · Stroke (3) · Carcinoma, Non-Small-Cell Lung (2) · Cardiovascular Diseases (2) · Critical Illness (2)
Embolism and Thrombosis (108) · Vascular Diseases (108) · Cardiovascular Diseases (107) · Pathological Conditions, Signs and Symptoms (30) · Pathologic Processes (28) · Respiratory Tract Diseases (26) · Lung Diseases (25) · Embolism (21) · Thrombosis (20) · Neoplasms (13) · Heart Diseases (12) · Neoplasms by Site (12) · Nervous System Diseases (10) · Urogenital Diseases (9)
Enoxaparin (18) · apixaban (15) · Rivaroxaban (14) · Aspirin (8) · Dalteparin (7) · Tinzaparin (6) · Heparin (5) · Tranexamic Acid (5) · Warfarin (5) · Fondaparinux (4) · enoxaparin sodium (4) · Heparin, Low-Molecular-Weight (3) · Nadroparin (3) · Rosuvastatin Calcium (3) · Sodium Chloride (3)
Beijing Chao Yang Hospital (3) · Ottawa Hospital Research Institute (3) · University of Calgary (3) · Utrecht Institute for Pharmaceutical Sciences (3) · Brigham and Women's Hospital (2) · Duke University (2) · Intermountain Health Care, Inc. (2) · Les Laboratoires des Médicaments Stériles (2) · Medical University of Vienna (2) · Oregon Health and Science University (2) · Pfizer (2) · Science Valley Research Institute (2) · Tampere University Hospital (2) · Arianna Anticoagulazione Foundation (1) · Asan Medical Center (1)
United States (31) · Canada (17) · China (8) · France (8) · Austria (6) · Netherlands (6) · Australia (5) · Germany (5) · Italy (5) · South Korea (5) · Spain (5) · Switzerland (5) · Israel (4) · United Kingdom (4) · Belgium (3)
Eduardo Ramacciotti, MD, Ph.D. (2) · Lana Castellucci, MD, FRCPC (2) · Russell D Hull, MBBS, MSc (2) · Ahmad Uzair Qureshi, FCPS (1) · Alessandro Squizzato, MD (1) · Anne Munck, MD (1) · Anne-Mette Hvas, MD (1) · Annick Steib, MD (1) · Antoni Romera, MD (1) · Azhar Supariwala, MD (1) · Banne Nemeth, dr (1) · Bernhard Meier, MD (1) · Bob Smouse, MD (1)
PMID 24251360, PMID 28063245, PMID 35244208, PMID 10453824, PMID 10546719, PMID 12387283, PMID 12709915, PMID 12763484, PMID 12825542, PMID 15383488, PMID 16287790, PMID 17065639, PMID 18248600, PMID 18572147, PMID 18827132, PMID 19741062, PMID 20040086, PMID 20352167, PMID 20553388, PMID 20621900, PMID 20797774, PMID 21309005, PMID 21356042, PMID 21798429, PMID 21860314, PMID 21923455, PMID 22315276, PMID 22863355, PMID 22925036, PMID 23117723, PMID 23245654, PMID 23246393, PMID 23306310, PMID 23514285, PMID 24251363, PMID 24519568, PMID 26835109, PMID 27488365, PMID 27959709, PMID 28146651, PMID 28492441, PMID 28762617, PMID 29270080, PMID 29526139, PMID 29655662, PMID 30352714, PMID 31064405, PMID 31643128, PMID 31926776, PMID 32346486
2009 (2), 2023 (2), 2008 (1), 2014 (1), 2017 (1), 2019 (1), R34HL159119 (1), UG3HL176627 (1)